Volume 7.27 | Jul 24

Immune Regulation News 7.27 July 24, 2015
Immune Regulation News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Like Us on Facebook   IRN on Twitter
Cell Division Speeds Up as Part of Antibody Selection
Scientists uncovered a new mechanism by which the B cells that produce the most finely tuned antibodies rise to dominance. Through a process called affinity, maturation B cells compete, and those cells that produce the highest affinity antibodies win and come to dominate the B cell population. [Press release from The Rockefeller University discussing online prepublication in Science] Press Release | Abstract
Isolate Immune Cells From Whole Blood Without Lysis or Centrifugation with EasySep™ Direct. Request a Free Sample!
PUBLICATIONS (Ranked by impact factor of the journal)
Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy
Researchers developed an enrichment + expansion strategy using paramagnetic, nanoscale artificial antigen presenting cells to rapidly expand tumor-specific T cells from rare naïve precursors and predicted neo-epitope responses. [ACS Nano] Abstract | Graphical Abstract | Press Release

Phosphorylation Status Determines the Opposing Functions of Smad2/Smad3 as STAT3 Cofactors in TH17 Differentiation
Investigators showed that the highly homologous transforming growth factor-β receptor-regulated Smads: Smad2 and Smad3 oppositely modify STAT3-induced transcription of interleukin-17A and retinoic acid receptor-related orphan nuclear receptor, RORγt encoded by Rorc, by acting as a co-activator and co-repressor of STAT3, respectively. [Nat Commun] Full Article

MicroRNA-31 Negatively Regulates Peripherally Derived Regulatory T-Cell Generation by Repressing Retinoic Acid-Inducible Protein 3
Investigators showed that T-cell receptor signaling induces microRNA (miR)-31, which negatively regulates peripherally derived regulatory T (pTreg)-cell generation. miR-31 conditional deletion results in enhanced induction of pTreg cells, and decreased severity of experimental autoimmune encephalomyelitis. [Nat Commun] Full Article

Adiponectin Regulates Psoriasiform Skin Inflammation by Suppressing IL-17 Production from γδ-T Cells
Scientists demonstrated that adiponectin regulates skin inflammation, especially IL-17-related psoriasiform dermatitis. Mice with adiponectin deficiency showed severe psoriasiform skin inflammation with enhanced infiltration of IL-17-producing dermal Vγ4+γδ-T cells. [Nat Commun] Abstract

Multiplex Genome Edited T-Cell Manufacturing Platform For “Off-The-Shelf” Adoptive T-Cell Immunotherapies
Researchers used a transcription activator-like effector nuclease-mediated editing approach to develop a process for the large-scale manufacturing of T-cells deficient in expression of both their T-cell receptor and CD52, a protein targeted by alemtuzumab, a chemotherapeutic agent. [Cancer Res] Abstract | Press Release

Regulatory B Cells Preferentially Accumulate in Tumor-Draining Lymph Nodes and Promote Tumor Growth
Investigators showed that phenotypic characterization of lymphocytes in mice bearing B16-F10 melanomas identifies preferential accumulation of T2-MZP B cells in the tumor-draining popliteal lymph. [Sci Rep] Full Article

Peripherally Induced Tolerance Depends on Peripheral Regulatory T Cells that Require Hopx To Inhibit Intrinsic IL-2 Expression
The authors report that homeodomain-only protein (Hopx)+ peripheral regulatory T cells converted by dendritic cells from Hopx-T cells are indispensible to sustain tolerance that prevents autoimmune responses directed at self-Ags during experimental acute encephalomyelitis. [J Immunol] Abstract

CCR4 Controls the Suppressive Effects of Regulatory T Cells on Early and Late Events during Severe Sepsis
Scientists investigated the role of CCR4, the CCL17/CCL22 chemokine receptor, in the innate and acquired immune responses during severe sepsis and the role of regulatory T cells in effecting the outcome. [PLoS One] Full Article

Don’t forget to subscribe to Human Immunology News and Immunology of Infectious Disease News!

Request a Sample: 8 minutes to highly purified immune cells with EasySep™.
Molecular and Cellular Insights into T Cell Exhaustion
The authors review recent advances that provide a clearer molecular understanding of T cell exhaustion and reveal new therapeutic targets for persisting infections and cancer. [Nat Rev Immunol] Abstract

Visit our reviews page to see a complete list of reviews in the immune regulation research field.

Save 15% off standard rates to Immuno-Oncology 2015!
Argos Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase III ADAPT Clinical Trial of AGS-003
Argos Therapeutics Inc. announced the pivotal Phase III ADAPT clinical trial of AGS-003 in combination with standard targeted therapy for the treatment of metastatic renal cell carcinoma has reached its enrollment goal of at least 450 randomized patients. [Argos Therapeutics] Press Release

Agenus Acquires Novel Antibodies to Immuno-Oncology Target CEACAM1
Agenus Inc. announced that it has acquired rights to antibodies targeting carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1), a glycoprotein expressed on T cell and NK cell lymphocytes from Diatheva s.r.l. CEACAM1 that is overexpressed in melanoma, bladder, lung, colon, pancreas, and gastric cancers and has been shown to modulate innate and adaptive immune suppression in pre-clinical studies. [Agenus Inc.] Press Release

Molecular Partners Confirms Its Focus on Proprietary Oncology Pipeline – Discovery Alliance with Roche Discontinued
Molecular Partners AG reiterated its commitment to its un-partnered pipeline. This includes advancing the clinical and preclinical development pipeline and ramping up the activities in immuno-oncology. Following Molecular Partners’ expansion of its strategic ophthalmology partnership with Allergan, the company confirmed the discontinuation of the DARPin-toxin alliance with Roche. [Molecular Partners AG] Press Release

ZIOPHARM Announces Orphan Drug Designation for Ad-RTS-hIL-12 in the Treatment of Malignant Glioma
ZIOPHARM Oncology, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for Ad-RTS-hIL-12 + veledimex in the treatment of patients with malignant glioma. Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T cell immune response. [ZIOPHARM Oncology, Inc.] Press Release

From our sponsor: Studying ESCs or iPSCs? Request your free copy of the small molecules wallchart.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW The 15th International Conference on Progress in Vaccination Against Cancer (PIVAC-15)
October 6-8, 2015
Tübingen, Germany

Visit our events page to see a complete list of events in the immune regulation community.
NEW Research Associate – Cell Biology (Editas Medicine)

NEW Senior Research Associate – CRISPR-Based Therapeutics (Editas Medicine)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Scientific Marketing Specialist – Immunology (STEMCELL Technologies Inc.)

Research Assistant – Immunotherapy for HIV Infection (California Institute of Technology)

Postdoctoral Position – Translational Immunology (University of Utah School of Medicine)

PhD Studentship – Veterinary and Animal Sciences (University of Milan)

Postdoctoral Researcher – Tumorigenesis and Immune Response (Nationwide Children Hospital-Ohio)

Senior Scientist – Immunology (Valera LLC)

Postdoctoral Fellow – Antibody Engineering/Immuno-Oncology (California Institute for Biomedical Research)

Associate Director/Director – Immunology (Valera)

Postdoctoral Fellow – Immune Reconstitution in Hematopoietic Stem Cell Transplantation (Stanford University)

Process Facilitator (Opexa Therapeutics)

Assistant Professor – Immunology (Northwestern University)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Immune Regulation News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Immune Regulation News: Archives | Events | Contact Us